FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC
Byoung Chul Cho(Yonsei University), Tony Mok(Chinese University of Hong Kong), G. Lopes(University of Miami), Igor Bondarenko(Dnipro State Medical University), Iveta Kudaba(Riga East University Hospital), Francis Ribeiro de Souza(Merck & Co., Inc., Rahway, NJ, USA (United States)), Dariusz M. Kowalski(The Maria Sklodowska-Curie National Research Institute of Oncology), Vichien Srimuninnimit(Siriraj Hospital), К. К. Лактионов(Russian Cancer Research Center NN Blokhin), L. Zhang(Sun Yat-sen University), Gilberto de Castro(Instituto do Câncer do Estado de São Paulo), Bogusława Karaszewska(State University of Applied Sciences in Konin), Yi‐Long Wu(Guangdong Academy of Medical Sciences), H.Z. Turna(Istanbul University-Cerrahpaşa), J. Lin(Merck & Co., Inc., Rahway, NJ, USA (United States)), Kazuo Kubota(Stony Brook University), Christian Caglevic
Cited by 28
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k